Viral Vector Manufacturing: Global Leaders Scale Up Capacity with Advanced Platforms and Strategic Acquisitions

August 17, 2026

The Business Research Company International

Overview

The viral vector manufacturing market is experiencing rapid expansion as major players intensify efforts to scale production for gene therapies and vaccines. Recent strategic moves include AGC Biologics’ launch of BravoAAV and ProntoLVV platforms, promising rapid GMP product delivery, and Oxford Biomedica’s acquisition of ABL Europe to broaden its CDMO services. These initiatives reflect a market-wide drive to streamline development and accelerate the commercialization of advanced genetic medicines.

In Depth

Background

This article provides an overview of a market research report published by The Business Research Company, a global market intelligence firm renowned for its comprehensive market research, analyst insights, and consulting services across various industries. The report focuses on the dynamic viral vector manufacturing market, identifying key trends such as the development of advanced manufacturing platforms and strategic mergers and acquisitions aimed at bolstering production capabilities.

Key Findings

In response to escalating demand, leading companies within the viral vector manufacturing market are aggressively pursuing the development of advanced platforms designed to significantly streamline and scale production processes for both gene therapy and vaccine applications. This strategic focus is crucial for enhancing market competitiveness and meeting global needs efficiently.
A prime example is AGC Biologics, which in May 2023 introduced its BravoAAV and ProntoLVV platforms. These innovative solutions are engineered to guarantee the delivery of Good Manufacturing Practice (GMP)-compliant products within a rapid nine-month timeframe, substantially compressing critical development timelines for their clients.
Further demonstrating market consolidation and capability expansion, Oxford Biomedica acquired ABL Europe in January 2024. This strategic acquisition significantly enhances Oxford Biomedica’s multi-viral vector Contract Development and Manufacturing Organization (CDMO) service capabilities, positioning the company to address a wider range of customer requirements across various viral vector types.
These recent developments clearly indicate an accelerating pace of innovation and industry integration within the viral vector manufacturing sector. Such advancements are absolutely critical for overcoming bottlenecks and fast-tracking the development and subsequent commercialization of life-changing gene therapies.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.